GSK bolsters vaccine business with Merck cast-off
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline has acquired Swiss vaccine developer Okairos for €250 million in cash. The privately held firm was spun out of Merck & Co in 2007.